Global Ganja Report

Having just undertaken a "critical study" of CBD, the non-psychoactive cannabinoid held to have multifarious medicinal applications, the World Health Organization is now opening such a study on THC. Stigmatized due to its psychoactive properties and currently in the shadow of the suddenly sexy CBD, tetrahydrocannabinol shows its own potential for application by the medical industry.

The British government has finally capitulated to pressure from patients, activists and even regional authorities, and officially pledged to make medical cannabis products available on prescription this year. But it remains to be seen which products will win approval—and actual herbaceous cannabis is unlikely to make the cut.

California health authorities dealt a blow to the burgeoning CBD business by banning preparations of the cannabinoid derived from industrial hemp rather than psychoactive cannabis. The diktat adds to the legal confusion around CBD, and highlights the need for greater clarity from the competent authorities at both the state and federal level.

A federal appeals court has turned down a challenge by the cannabis industry to the DEA's official finding that CBD is a controlled substance. But questions about whether CBD should be treated as a controlled substance remain pending at the state level.

A judge for the US District Court for the Southern District of New York on Feb. 26 dismissed a lawsuit challenging the Schedule I classification for cannabis under the Controlled Substances Act. Judge Alvin Hellerstein granted the government's motion to dismiss because the plaintiffs failed to exhaust all administrative remedies prior to initiating the suit. The "exhaustion rule" requires "that parties exhaust prescribed administrative remedies before seeking relief from federal courts."

Medical marijuana advocates and bureaucrats from regulatory agencies around the world have both been awaiting a statement on the risks and benefits of cannabidiol (CBD) from the World Health Organization's Expert Committee on Drug Dependence (ECDD). Now the assessment on the non-psychoactive cannabinoid is in, and it is encouraging news for those who have been hoping for its removal from Schedule 1, the international designation for drugs with no therapeutic value but high potential for abuse.

Amid the legal ambiguities about the status of cannabidiol (CBD), authorities in one state that had cracked down on preparations of the salutary cannabinoid are now admitting that they themselves are confused. Weeks after Indiana State Excise Police declared products containing CBD oil to be illegal—and carrying out a raid on an Indianapolis-aread natural goods store to prove it—state officials say they don’t actually know if CBD oil products are illegal or not.

The number of drug-related offenses is "higher than any other heinous crime in Nepal and is increasing at an alarming rate," according a none-too-objective March 17 account in Kathmandu's The Himalayan newspaper. The article credulously regurgitates the claims of a new report from the country's Narcotics Control Bureau, breaking down crime figures since 2011. The total for drug offenses rises to around 1,800, while those for murder and rape remain in the hudreds, and abduction in the two-digit range. And what kinds of drugs are at issue here? We are luridly told that "cultivation of genetically selected strains have [sic] led to increase in cannabis harvests. As a result, cannabis cultivation is increasing even in the hilly areas, posing a grave threat to security, according to the report."